Close Menu

NEW YORK – Tangen Biosciences said on Thursday that it has closed a $12.2 million Series B preferred stock financing with participation from current and new investors, including Connecticut Innovations, VC23, Leading Edge Ventures, and Parvizi Surgical. The financing was oversubscribed from the initial $10 million target.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.